Paratek Pharmaceuticals, Inc. (PRTK): Price and Financial Metrics


Paratek Pharmaceuticals, Inc. (PRTK): $2.09

-0.02 (-0.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRTK to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PRTK POWR Grades

  • Growth is the dimension where PRTK ranks best; there it ranks ahead of 94.08% of US stocks.
  • PRTK's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • PRTK ranks lowest in Momentum; there it ranks in the 5th percentile.

PRTK Stock Summary

  • PARATEK PHARMACEUTICALS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.43% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.16 for PARATEK PHARMACEUTICALS INC; that's greater than it is for merely 5.35% of US stocks.
  • Over the past twelve months, PRTK has reported earnings growth of 108.93%, putting it ahead of 87.06% of US stocks in our set.
  • Stocks that are quantitatively similar to PRTK, based on their financial statements, market capitalization, and price volatility, are AMRS, PHUN, AXGN, OSIS, and HEAR.
  • Visit PRTK's SEC page to see the company's official filings. To visit the company's web site, go to paratekpharma.com.

PRTK Valuation Summary

  • In comparison to the median Healthcare stock, PRTK's price/sales ratio is 80.39% lower, now standing at 1.
  • PRTK's EV/EBIT ratio has moved down 4.9 over the prior 170 months.

Below are key valuation metrics over time for PRTK.

Stock Date P/S P/B P/E EV/EBIT
PRTK 2023-01-20 1.0 -0.7 -1.3 -5.0
PRTK 2023-01-19 1.0 -0.7 -1.3 -4.9
PRTK 2023-01-18 1.0 -0.7 -1.3 -5.0
PRTK 2023-01-17 1.1 -0.8 -1.5 -5.1
PRTK 2023-01-13 1.1 -0.8 -1.5 -5.2
PRTK 2023-01-12 1.2 -0.8 -1.5 -5.2

PRTK Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at 53.14%.
  • Its 4 year net cashflow from operations growth rate is now at -27.96%.
  • The 5 year price growth rate now stands at -80.42%.
PRTK's revenue has moved up $116,461,000 over the prior 67 months.

The table below shows PRTK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 116.508 -65.836 -88.662
2022-06-30 110.742 -27.158 -85.984
2022-03-31 138.597 -45.865 -58.648
2021-12-31 130.162 -48.273 -59.084
2021-09-30 114.387 -52.315 -51.841
2021-06-30 103.599 -107.493 -54.494

PRTK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PRTK has a Quality Grade of D, ranking ahead of 16.58% of graded US stocks.
  • PRTK's asset turnover comes in at 0.58 -- ranking 64th of 680 Pharmaceutical Products stocks.
  • BHVN, EVFM, and IBRX are the stocks whose asset turnover ratios are most correlated with PRTK.

The table below shows PRTK's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.580 0.831 -0.114
2021-03-31 0.291 0.821 -0.222
2020-12-31 0.224 0.816 -0.242
2020-09-30 0.175 0.812 -0.234
2020-06-30 0.125 0.787 -0.259
2020-03-31 0.090 0.792 -0.276

PRTK Price Target

For more insight on analysts targets of PRTK, see our PRTK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.75 Average Broker Recommendation 1.25 (Strong Buy)

PRTK Stock Price Chart Interactive Chart >

Price chart for PRTK

PRTK Price/Volume Stats

Current price $2.09 52-week high $4.37
Prev. close $2.11 52-week low $1.60
Day low $2.07 Volume 205,300
Day high $2.14 Avg. volume 313,194
50-day MA $2.05 Dividend yield N/A
200-day MA $2.35 Market Cap 116.10M

Paratek Pharmaceuticals, Inc. (PRTK) Company Bio


Paratek Pharmaceuticals focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. The company was founded in 1996 and is based in in Boston, Massachusetts.


PRTK Latest News Stream


Event/Time News Detail
Loading, please wait...

PRTK Latest Social Stream


Loading social stream, please wait...

View Full PRTK Social Stream

Latest PRTK News From Around the Web

Below are the latest news stories about PARATEK PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PRTK as an investment opportunity.

BAND, PRTK and OTLY are among after hour movers

  • Gainers: AC Immune (ACIU) +1%.
  • BuzzFeed (BZFD) +1%.
  • Oatly Group  (OTLY) +1%.
  • DICE Therapeutics (DICE) Seeking Alpha | January 26, 2023

Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)

National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure InfectionsBOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquir

Yahoo | January 18, 2023

Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract

Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of Pulmonary Anthrax Announced in December BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced the receipt of a $36.4 million milestone payment associated with the second procurement of NUZYRA® (omadacycline) under the company’s Project BioShield contract w

Yahoo | January 5, 2023

Individual investors account for 39% of Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) ownership, while institutions account for 38%

If you want to know who really controls Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ), then you'll have to look at the...

Yahoo | January 2, 2023

Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board

BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company’s independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected unanimously by the independent directors of the Board, in recognition of his extensive leadership experience, in-depth knowledge of Paratek and the business of the anti-infective industry, strong financial and operation

Yahoo | December 20, 2022

Read More 'PRTK' Stories Here

PRTK Price Returns

1-mo 14.84%
3-mo -40.96%
6-mo -7.11%
1-year -43.89%
3-year -39.77%
5-year -86.47%
YTD 11.76%
2022 -58.35%
2021 -28.27%
2020 55.33%
2019 -21.44%
2018 -71.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7931 seconds.